Teva Announces Pricing of €2 Billion of Senior Notes

March 26, 2015

Willkie assists longtime pharmaceutical client in multi-tranche Eurobond offering. 

Teva Pharmaceutical Industries Limited announced that it priced a €2 billion Eurobond offering, comprised of two tranches: €1.3 billion principal amount of 1.250% senior notes due March 2023 and €700 million principal amount of 1.875% senior notes due March 2027. The notes, issued by Teva Pharmaceutical Finance Netherlands II B.V., a finance subsidiary of Teva, will be guaranteed by Teva.  Willkie recently assisted Teva in its multi-tier $1.3 billion debt tender offer. The Willkie team was led by Jeffrey Hochman and included Julian Golay, Katherine Lynch and Jonathan Kubek, as well as Jon Lyman and Jennifer Tait from the London office.